2022 Highlights of ASH

Coeur d'Alene, ID US
February 19, 2022

OUR CONFERENCE WILL PROVIDE RAPID ANTIGEN COVID19 TESTING FOR ALL ATTENDEES AND FACULTY.

The 2022 Highlights of ASH is a CME-accredited, in-person hematology conference featuring leading experts in the field. This conference allows professionals an opportunity to discuss current research and advances in the field of blood disorders and hematologic malignancies with colleagues and key opinion leaders. Expert faculty will place key abstract findings from the 63rd ASH Annual Meeting into clinical context and discuss how the results may change the current standard of care. The goals of this conference are to review and critically assess practice-changing results of practice-changing clinical data and expert recommendations to optimize clinical outcomes for the patients. 

Conference Highlights: 

1.    Audience response system

2.    Didactics and case-based discussions

3.    Core competencies covered include patient care/patient-centered care, medical knowledge, system-based practice, and practice-based learning and improvement.

4.    Opportunities to network with colleagues and faculty members.

5.    Program topics can immediately be applied to clinical practice.

Target Audience

  • Hematologists/Oncologists
  • Oncology and hematology residents/fellows
  • Oncology and hematology NPs/PAs
  • Oncology and hematology pharmacists
  • Oncology and hematology nurses

Learning Objectives

At the conclusion of the activity, participants will be able to:

  • Review data presented at the 63rd ASH Annual Meeting (2021) and discuss their application in clinical settings
  • Discuss the study design and primary endpoints of recently reported and ongoing trials that have influenced the changes in the standards of care for patients with blood disorders and hematologic malignancies
  • Identify side effects, indications, and contra-indications of various therapies used to diagnose and treat blood disorders and hematologic malignancies, and explain how to effectively manage those side-effects
  • Integrate emerging evidence into treatment paradigms for treatment of patients with blood disorders and hematologic malignancies
Course summary
Available credit: 
  • 6.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 6.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.50 Contact Hours.
Course opens: 
08/22/2021
Course expires: 
03/19/2022
Event starts: 
02/19/2022 - 7:00am PST
Event ends: 
02/19/2022 - 5:00pm PST
Cost:
$200.00

Conference Chair: Srinivas Tantravahi, MBBS, MRCP(UK)

All time listed below are in Pacific Standard Time.

06:30 AM - 07:45 AM PST:            Registration/Networking

07:45 AM - 08:00 AM PST:            Opening remarks


Moderator: Srinivas Tantravahi, MBBS, MRCP(UK)

08:00 AM - 08:30 AM PST:            Myelodysplastic Syndromes - Paul Shami, MD

08:30 AM - 09:00 AM PST:            Myeloproliferative neoplasms including Chronic Myeloid Leukemia - Irum Khan, MD

09:00 AM - 09:30 AM PST:            Acquired Bone Marrow Failure Syndromes - Srinivas Tantravahi, MBBS, MRCP(UK)


09:30 AM - 10:00 AM PST:           Break & exhibits


Moderator: Binay Shah, MD, MPH

10:00 AM - 10:30 AM PST:            ITP/TTP, aHUS - George Rodgers III, MD, PhD

10:30 AM - 11:00 AM PST:            Clotting disorders - Doris V. Quon, MD, PhD

11:00 AM - 11:30 PM PST:             Bleeding disorders - Beth Warren, MD

11:30 AM - 12:00 PM PST:             Q&A


12:00 PM - 01:00 PM PST:             Lunch & exhibits


Moderator: Arvind Chaudhry, MD, PhD

01:00 PM - 01:30 PM PST:             Chronic Lymphocytic Leukemia - Parameswaran Venugopal, MD

01:30 PM - 02:00 PM PST:             Lymphoma - Grzegorz S. Nowakowski, MD  

02:00 PM - 02:30 PM PST:             Q&A


02:30 PM - 03:00 PM PST:             Break & exhibits


Moderator: Srinivas Tantravahi, MBBS, MRCP(UK)

03:00 PM - 03:30 PM PST:             Acute Leukemia - Jacob S. Appelbaum, MD, PhD

03:30 PM - 04:00 PM PST:             Myeloma - Shaji Kumar, MD

04:00 PM - 04:30 PM PST:             Q&A


04:30 PM - 04:35 PM PST:            Adjourn

Coeur d'Alene Resort, Coeur d'Alene, Idaho
115 S 2nd St
Coeur d'Alene, ID 83814
United States

RESERVE YOUR ROOM AT THE COEUR D'ALENE RESORT

A limited number of rooms have been booked at the Coeur d'Alene Resort for the attendees of the 2022 Highlights from ASH. You can reach the Reservations Department by calling 888-965-6542. When calling this number, you will need to press #2, then #1 for Group Reservations.  When calling in you can refer to the Block Code: BINAYTARA222.

Lake Tower$199.00
Park Tower$179.00
North Wing$159.00

Travel

Traveling by Air

The Coeur d'Alene Resort is located 40 minutes east of the Spokane International Airport, offering nonstop or one-stop access from most major US and Canadian cities. The Coeur d’Alene Air Terminal is available for corporate and private aircraft.

Airport limousine service is available from both the Spokane and Coeur d'Alene facilities with advance reservations. The fee for the shuttle is $69/person roundtrip (please confirm with the venue and pre-book the shuttle).

Traveling by Car

The Coeur d'Alene Resort is easy to reach by automobile via Interstate 90 (Exit 11) or Highway 95 (Northwest Blvd). From the exit, follow the directions to downtown and watch for the Resort on your right.

All relevant financial relationships of individuals in control of the content have been identified and mitigated. No members of this activity's planning committee or faculty have any relevant financial relationship with an ineligible entity except for the following faculties: 

  • Dr. Grzegorz Nowakowski Commercial Interest(s): Celgene/BMS, Relationship: Consultant, Commercial Interest(s) MorphoSys, Relationship: Research support/Grant, Consultant, Commercial Interest(s): Roche/Genentech , Relationship: Consultant, Commercial Interest(s): Kite, Relationship: Consultant, Commercial Interest(s): TG Therapeutics, Relationship: Consultant, Commercial Interest(s): Ryvu, Relationship: Consultant, Commercial Interest(s): MEI, Relationship: Consultant
  • Dr. Irum Khan:  Commercial Interest(s): Bristol Myers Squibb, Relationship: Other, Please list if you selected other): Advisory Board
  • Dr. Paul Shami has a Commercial Interest(s): BMS, Relationship: Consultant, Commercial Interest(s): Bastion Biologic, Relationship: Speakers Bureau, Chief Medical Advisor, Chimerix, Relationship: Research support/Grant, Commercial Interest(s): JSK Therapeutics, Relationship: Other, Founder, Stock Holder, Chief Medical Officer, Commercial Interest(s): RJH Biosciences, Relationship: Consultant, Commercial Interest(s): Amgen, Relationship: Research support/Grant, Commercial Interest(s): Aptevo, Relationship: Research support/Grant, Commercial Interest(s): ONO, Relationship: Research support/Grant
  • Dr.Beth Warren has no relevant financial relationship to disclose. Off-label discussion: Dr. Warren will review ASH talk of emicizumab use in persons with acquired hemophilia A.
Speaker(s)

David Aboulafia, MD

has no relevant financial relationships to disclose at this time.

Jacob Appelbaum, MD/PhD

has no relevant financial relationships to disclose at this time.

Arvind Chaudhry, MD, PhD

has no relevant financial relationships to disclose at this time.

Binod Dhakal, MD, MS

has a financial relationship (Other) with GSK;.
has a financial relationship (Other) with Natera;.
has a financial relationship (Other) with Sanofi;.
has a financial relationship (Other) with Celgene/BMS;.
has a financial relationship (Other) with Janssen;.
has a financial relationship (Other) with Amgen;.

Shaji Kumar, MD

has a financial relationship (Grant Or Contract) with Research funding for clinical trials to the institution: Abbvie, Amgen, BMS, Carsgen,  Janssen,  ,  Astra-Zeneca, Novartis, Roche-Genentech,  Takeda, Tenebio, Molecular Templates;.
has a financial relationship (Professional Services) with Consulting/Advisory Board participation: (with no personal payments) Abbvie, Amgen, BMS, Janssen,  Roche-Genentech, Takeda, Astra-Zeneca, Bluebird Bio, Epizyme, Secure Biotherapeutics and (with personal payment) Oncopeptides, Beigene, Antengene ;.

Doris Quon, MD, PhD

has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Professional Services) with uniQure;.
has a financial relationship (Professional Services) with Biomarin;.
has a financial relationship (Professional Services) with Octapharma;.
has a financial relationship (Professional Services) with Bayer;.
has a financial relationship (Professional Services) with Roche/Genentech;.
has a financial relationship (Professional Services) with NovoNordisk;.
has a financial relationship (Professional Services) with Takeda;.

GEORGE RODGERS, MD, PhD

has a financial relationship (Professional Services) with Argenx;.
has a financial relationship (Professional Services) with Dova;.

Paul Shami

has a financial relationship (Other) with RJH Biosciences;.
has a financial relationship (Grant Or Contract) with ONO;.
has a financial relationship (Other) with JSK Therapeutics;.
has a financial relationship (Grant Or Contract) with Aptevo;.
has a financial relationship (Other) with Bastion Biologic;.
has a financial relationship (Other) with BMS;.
has a financial relationship (Grant Or Contract) with Amgen;.

Srinivas Tantravahi, MBBS; MRCP

has a financial relationship (Financial Support) with karyopharm therapeutics;.
has a financial relationship (Professional Services) with Novartis;.

Parameswaran Venugopal, MD

has a financial relationship (Professional Services) with AstraZeneca;.

Prakash Vishnu

has no relevant financial relationships to disclose at this time.

Commercial Support Acknowledgement:

This activity has been supported with an independent medical education grant from Pharmacosmos. 

 

Available Credit

  • 6.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 6.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.50 Contact Hours.

Please visit our exhibitors in Bay 4.

Price

Cost:
$200.00
Please login or register to take this course.

Physicians (MD/DO) - $200

Non-Physician (RN/NP/PA/PharmD) - $75 

 

Industry Registration

Non-displaying industry representative - $850

Displaying industry representative (not covered by the display fee) - $650 (Displaying reps must register using this link - https://education.binayfoundation.org/industry_registraiton_nocme)

If you are employed by the industry, you must register as "Industry representative" even if you are a licensed healthcare provider not involved in the sales of product. The industry price is applicable to everyone who are employed by an ACCME defined ineligible company. 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.